Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

A. Sureda, D. Isla, J. M. Cózar, M. Ruiz, M. Domine, M. Margelí, E. Adrover, M. Ramos, M. Pastor, A. Martín, A. Llombart, B. Massuti, M. Muñoz, A. Barnadas, J. Fernández, R. Colomer, C. Allepuz, M. Gilabert, X. Badia*

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

16 Cites (Scopus)

Resum

This paper describes the final development and validation of the BOMET-QoL questionnaire for assessing health-related quality of life (HRQoL) in patients with malignant bone disease due to neoplasia (MBDN). An observational prospective study was conducted of 263 patients with MBDN. Sociodemographic and clinical variables, Eastern Cooperative Oncology Group (ECOG) Performance Scale Index and Pain Management Index (PMI) were gathered. Patients completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and BOMET-QoL questionnaires and the perception of general health status. Both questionnaires were completed again 15 days after the baseline visit by 98 clinically stable patients (Group A), and 3 months and 6 months after the baseline visit by 165 clinically unstable patients (Group B). Prior to validation of the BOMET-QoL questionnaire, a factor analysis and psychometric selection of the original items was developed by means of Rasch analysis. The BOMET-QoL questionnaire consisting of 25 items was reduced to an integrated version of 10 items. Scores on the BOMET-QoL-10 questionnaire were shown to be related to the presence, number and duration of irruptive pain crises, the PMI and the ECOG index (p
Idioma originalAnglès
Pàgines (de-a)27-39
Nombre de pàgines13
RevistaJournal of Medical Economics
Volum10
Número1
DOIs
Estat de la publicacióPublicada - 2007

Fingerprint

Navegar pels temes de recerca de 'Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia'. Junts formen un fingerprint únic.

Com citar-ho